Amedeo Smart

Free Medical Literature Service


 

Amedeo

Lung Cancer

  Free Subscription

Articles published in
J Clin Invest
    March 2024
  1. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    >> Share

    January 2024
  2. PEYVANDI S, Bulliard M, Yilmaz A, Kauzlaric A, et al
    Tumor-educated Gr1+CD11b+ cells drive breast cancer metastasis via OSM/IL6-JAK-induced cancer cell plasticity.
    J Clin Invest. 2024 Jan 18:e166847. doi: 10.1172/JCI166847.
    >> Share

  3. GHANBAR MI, Suresh K
    Pulmonary toxicity of immune checkpoint immunotherapy.
    J Clin Invest. 2024;134:e170503.
    >> Share

    December 2023
  4. JING N, Zhang K, Chen X, Liu K, et al
    ADORA2A-driven proline synthesis triggers epigenetic reprogramming in neuroendocrine prostate and lung cancers.
    J Clin Invest. 2023;133:e168670.
    >> Share

  5. WANG S, Iyer R, Han X, Wei J, et al
    CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
    J Clin Invest. 2023;133:e167728.
    >> Share

    November 2023
  6. MAKINEN N, Meyerson M
    Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer.
    J Clin Invest. 2023;133:e174171.
    >> Share

    October 2023
  7. LIU S, Saunders M, Mak TW
    Chemical carcinogens: implications for cancer treatment.
    J Clin Invest. 2023;133:e174319.
    >> Share

  8. HUANG M, Xia Y, Li K, Shao F, et al
    Carcinogen exposure enhances cancer immunogenicity by blocking the development of an immunosuppressive tumor microenvironment.
    J Clin Invest. 2023;133:e166494.
    >> Share

  9. WANG T, Dong Y, Huang Z, Zhang G, et al
    Antioxidants stimulate BACH1-dependent tumor angiogenesis.
    J Clin Invest. 2023;133:e169671.
    >> Share

    September 2023
  10. KONEN JM, Rodriguez BL, Wu H, Fradette JJ, et al
    Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer.
    J Clin Invest. 2023;133:e163128.
    >> Share

    August 2023
  11. MALCHERS F, Nogova L, van Attekum MH, Maas L, et al
    Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.
    J Clin Invest. 2023 Aug 22:e170217. doi: 10.1172/JCI170217.
    >> Share

    July 2023
  12. ATTIG J, Pape J, Doglio L, Kazachenka A, et al
    Human endogenous retrovirus onco-exaptation counters cancer cell senescence through calbindin.
    J Clin Invest. 2023;133:e164397.
    >> Share

    June 2023
  13. NARDI F, Perurena N, Schade AE, Li ZH, et al
    Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer.
    J Clin Invest. 2023 Jun 29:e167651. doi: 10.1172/JCI167651.
    >> Share

    April 2023
  14. SALMON M, Alvarez-Diaz R, Fustero-Torre C, Brehey O, et al
    Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
    J Clin Invest. 2023;133:e164413.
    >> Share

  15. HU Z, Yu X, Ding R, Liu B, et al
    Glycolysis drives STING signaling to facilitate dendritic cell antitumor function.
    J Clin Invest. 2023;133:e166031.
    >> Share

    March 2023
  16. JASPERS JE, Khan JF, Godfrey WD, Lopez AV, et al
    IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
    J Clin Invest. 2023 Mar 23:e166028. doi: 10.1172/JCI166028.
    >> Share

    February 2023
  17. TAN X, Xiao GY, Wang S, Shi L, et al
    EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
    J Clin Invest. 2023 Feb 9:e165863. doi: 10.1172/JCI165863.
    >> Share

    January 2023
  18. WANG S, Rong R, Yang DM, Fujimoto J, et al
    Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
    J Clin Invest. 2023;133:e160330.
    >> Share

  19. HU H, Cheng R, Wang Y, Wang X, et al
    Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47.
    J Clin Invest. 2023;133:e153470.
    >> Share

  20. DING L, Chen X, Zhang W, Dai X, et al
    Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling.
    J Clin Invest. 2023;133:e154754.
    >> Share

    December 2022
  21. ZHANG S, You X, Zheng Y, Shen Y, et al
    The UBE2C/CDH1/DEPTOR axis is an oncogene-tumor suppressor cascade in lung cancer cells.
    J Clin Invest. 2022 Dec 22:e162434. doi: 10.1172/JCI162434.
    >> Share

    November 2022
  22. LI K, Liu Y, Ding Y, Zhang Z, et al
    BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.
    J Clin Invest. 2022;132.
    >> Share

  23. ZHANG H, Zhu X, Friesen TJ, Kwak JW, et al
    Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils.
    J Clin Invest. 2022;132.
    >> Share

    September 2022
  24. NIE M, Chen N, Pang H, Jiang T, et al
    Targeting acetylcholine signaling modulates persistent drug tolerance in EGFR-mutant lung cancer and impedes tumor relapse.
    J Clin Invest. 2022 Sep 1. pii: 160152. doi: 10.1172/JCI160152.
    >> Share

  25. WANG H, Lin Z, Nian Z, Zhang W, et al
    Hematopoietic transcription factor GFI1 promotes anchorage independence by sustaining ERK activity in cancer cells.
    J Clin Invest. 2022;132.
    >> Share

    August 2022
  26. HE Y, Luo W, Liu Y, Wang Y, et al
    IL20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer.
    J Clin Invest. 2022 Aug 25. pii: 157917. doi: 10.1172/JCI157917.
    >> Share

    June 2022
  27. YAN D, Huelse JM, Kireev D, Tan Z, et al
    MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
    J Clin Invest. 2022 Jun 16. pii: 150517. doi: 10.1172/JCI150517.
    >> Share

  28. DEFAYE M, Iftinca MC, Gadotti VM, Basso L, et al
    The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain.
    J Clin Invest. 2022;132.
    >> Share

    May 2022
  29. NANJO S, Wu W, Karachaliou N, Blakely CM, et al
    Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer.
    J Clin Invest. 2022 May 17. pii: 145099. doi: 10.1172/JCI145099.
    >> Share

    April 2022
  30. WAARTS MR, Stonestrom AJ, Park YC, Levine RL, et al
    Targeting mutations in cancer.
    J Clin Invest. 2022;132.
    >> Share

    March 2022
  31. XU C, Jin G, Wu H, Cui W, et al
    SIRPgamma-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling.
    J Clin Invest. 2022;132.
    >> Share

    February 2022
  32. MANABE T, Bivona TG
    Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    J Clin Invest. 2022;132.
    >> Share

  33. TSAI YS, Woodcock MG, Azam SH, Thorne LB, et al
    Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    J Clin Invest. 2022;132.
    >> Share

    November 2021
  34. MA B, Akosman B, Kamle S, Lee CM, et al
    CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses.
    J Clin Invest. 2021;131.
    >> Share

    October 2021
  35. ZHANG W, Sun Y, Bai L, Zhi L, et al
    RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11.
    J Clin Invest. 2021 Oct 5. pii: 152067. doi: 10.1172/JCI152067.
    >> Share

    September 2021
  36. HEISHIMA K, Sugito N, Soga T, Nishikawa M, et al
    Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis.
    J Clin Invest. 2021;131.
    >> Share

    August 2021
  37. SU SF, Ho H, Li JH, Wu MF, et al
    DNA methylome and transcriptome landscapes of cancer-associated fibroblasts reveal a smoking-associated malignancy index.
    J Clin Invest. 2021;131.
    >> Share

    May 2021
  38. MAIMON A, Levi-Yahid V, Ben-Meir K, Halpern A, et al
    Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10.
    J Clin Invest. 2021;131.
    >> Share

  39. LIANG W, Chen Z, Li C, Liu J, et al
    Accurate diagnosis of pulmonary nodules using a noninvasive DNA methylation test.
    J Clin Invest. 2021;131.
    >> Share

    January 2021
  40. SEHGAL K, Barbie DA
    Targeting the mutant p53 secretome.
    J Clin Invest. 2021;131.
    >> Share

  41. AMOEDO ND, Sarlak S, Obre E, Esteves P, et al
    Targeting the mitochondrial trifunctional protein restrains tumor growth in oxidative lung carcinomas.
    J Clin Invest. 2021;131.
    >> Share

  42. CHO J, Min HY, Lee HJ, Hyun SY, et al
    RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse.
    J Clin Invest. 2021;131.
    >> Share

  43. TAN X, Shi L, Banerjee P, Liu X, et al
    A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.
    J Clin Invest. 2021;131.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016